Generating value from innovation

In Healthcare & Life Sciences

Annual Report and Accounts for the year ended 31 December 2018

Who are we?

Arix Bioscience is a global venture capital company focused on investing in and building breakthrough biotech companies around cutting edge advances in life sciences.

We collaborate with exceptional entrepreneurs and provide the capital, expertise and global networks needed to help accerlerate their ideas into important new treatments for patients. As a listed company, we are able to bring this exciting growth phase of our industry to a broader range of investors.

Read more

Highlights

Net Asset Value (NAV)

£270m

(2017: £146m)

NAV PER SHARE*

£2.00

(2017: £1.52)

Gross Portfolio Value*

£175m

(2017: £54m)

£52m

Invested in Gross Portfolio

(2017: £50m)

26

Clinical trials across the portfolio

(Includes March 2019 Imara Investment)

19

Data readouts expected in 2019

£70m*

Net positive revaluation in the gross portfolio

$555m

Capital raised by portfolio companies in 2018

* Alternative Perfomance Measures

Financial Review

Our Discovery Portfolio Is important to the future development of the Core Portfolio as it provides a crèche to develop emerging innovation and explore commercial opportunities
Read more

Chairman's Statement

Our secondary offering in March 2018 raised additional funding for the Company, bringing the total funds raised to £250m since we formed the Company in 2016
Read more

Operational Review

I am pleased to report a year of positive progress; NAV increased over the year from 152p per share to 200p per share, a 32% increase
Read more